{
    "nctId": "NCT06578286",
    "briefTitle": "ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",
    "officialTitle": "Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Objective remission rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. 18 to 75 years old (including upper and lower limits), male or female;\n2. Unresectable locally advanced, recurrent or metastatic BC;\n3. Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);\n4. Received T-DXd treatment in the advanced stage;\n5. Adequate bone marrow, liver, kidney and coagulation function;\n6. Voluntarily sign the informed consent, have good compliance and are willing to comply with the follow-up visit.\n\nExclusion Criteria:\n\n1. With meningeal metastases or disseminated brain metastases or active brain metastases;\n2. Has interstitial lung disease requiring steroid therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;\n3. Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;\n4. Has cardiac insufficiency;\n5. Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}